Deutsche Bank raises Idorsia price target to CHF2.00 on Q2 beats

Deutsche Bank raised its price target for Idorsia (SIX:IDIA) to CHF2.00 from CHF1.00, while maintaining a Hold rating, following the Swiss pharmaceutical company's strong Q2 2025 revenue and non-GAAP operating profit beats and improved guidance. Despite Idorsia's confirmed progress toward overall profitability by 2027, Deutsche Bank noted limited upside potential from its in-line and pipeline portfolio. Specific concerns include Quviviq's U.S. growth dependency on DORA descheduling and Tryvio's lack of clinical competitiveness due to mild efficacy and persistent safety issues despite the removal of REMS from its U.S. label.

Analysis

Deutsche Bank has raised its price target on Idorsia to CHF2.00 from CHF1.00 but maintained a Hold rating, reflecting a mixed outlook for the Swiss pharmaceutical company. The price target increase was prompted by a strong Q2 2025 performance, where both revenue and non-GAAP operating profit significantly beat consensus estimates, leading management to issue improved guidance for the year. While management reaffirms its goal of achieving overall profitability by 2027, Deutsche Bank sees limited upside potential from Idorsia's current and pipeline assets. Specifically for Quviviq, its insomnia treatment, growth is positive in European markets but remains stable in the U.S., with future domestic growth highly dependent on the potential regulatory descheduling of the DORA class of medications. Furthermore, for its drug Tryvio, the removal of the REMS requirement from its U.S. label is a positive development, but the bank remains concerned about its clinical competitiveness, citing mild efficacy and persistent safety issues, along with a lack of clarity on partnership timing.

Key Decisions for Investors

• Investors should weigh Idorsia's strong near-term execution and improved guidance against the analyst's 'Hold' rating, which signals significant concerns about the long-term growth potential of its key drugs.
• Monitor specific upcoming catalysts, particularly any U.S. regulatory updates regarding the potential descheduling of the DORA drug class for Quviviq, as this is a key dependency for future sales growth.
• Scrutinize the competitive positioning of Tryvio, as its commercial success may be constrained by perceived weak efficacy and safety concerns, potentially overriding the benefit of recent positive label changes.